Reddigari S R, Kaplan A P
Department of Medicine, SUNY, Stony Brook 11794-8161.
Blood. 1989 Aug 1;74(2):695-702.
We developed a mouse monoclonal antibody (MoAb 115-21) to human high-molecular-weight kininogen (HK) that recognizes its prekallikrein binding site (residues 565 through 595 of HK). The corresponding synthesized 31-amino acid peptide (peptide IV) was recently shown to retain native HK's prekallikrein binding property. The same peptide bound factor XI also, although less avidly. Our MoAb recognizes purified HK, peptide IV, and the light chain moiety of HK (where the peptide IV resides), as shown by enzyme-linked immunosorbent assay (ELISA) and Western blotting experiments. The apparent dissociation constant for the HK and MoAb 115-21 interaction was 2.2 nmol/L. It does not recognize low-molecular-weight kininogen (LK) with which HK shares its heavy chain moiety or any antigens in human plasma congenitally deficient in kininogens. The binding of MoAb 115-21 to purified light chain of HK was competitively inhibited by peptide IV. In addition, the antibody inhibits HK-dependent clotting activity of normal human plasma and dextran sulfate-mediated activation of prekallikrein in plasma and retards cleavage of HK in normal plasma after contact activation with dextran sulfate. Also, purified Fab fragments of MoAb 115-21 inhibited the HK-dependent coagulant activity and dextran sulfate-mediated prekallikrein activation in normal plasma. Since the kd for HK-MoAb 115-21 interaction is ten times lower than that of HK-prekallikrein, our data suggest that binding of MoAb 115-21 to HK's peptide IV site increases the free prekallikrein concentration in plasma and thus results in the decreased efficiency of factor XIIa-mediated activation of prekallikrein. Decreased levels of kallikrein thus formed may be responsible for the inhibition of HK-dependent clotting activity and the decrease in rate and extent of HK cleavage in normal plasma on contact activation with dextran sulfate. MoAb 115-21 may thus prove very useful, especially with its high affinity for HK, in further delineation of the role of HK and prekallikrein in contact activation and kinin-related human pathology.
我们研发了一种针对人高分子量激肽原(HK)的小鼠单克隆抗体(MoAb 115 - 21),该抗体可识别其前激肽释放酶结合位点(HK的第565至595位氨基酸残基)。最近研究表明,相应合成的31个氨基酸的肽(肽IV)保留了天然HK的前激肽释放酶结合特性。同一肽也能结合因子XI,不过亲和力较低。如酶联免疫吸附测定(ELISA)和蛋白质印迹实验所示,我们的单克隆抗体可识别纯化的HK、肽IV以及HK的轻链部分(肽IV所在部位)。HK与MoAb 115 - 21相互作用的表观解离常数为2.2 nmol/L。它不识别与HK共享重链部分的低分子量激肽原(LK),也不识别先天性缺乏激肽原的人血浆中的任何抗原。肽IV可竞争性抑制MoAb 115 - 21与纯化的HK轻链的结合。此外,该抗体可抑制正常人血浆中HK依赖的凝血活性以及硫酸葡聚糖介导的血浆中前激肽释放酶的激活,并延缓硫酸葡聚糖接触激活后正常人血浆中HK的裂解。而且,纯化的MoAb 115 - 21 Fab片段可抑制正常人血浆中HK依赖的凝血活性以及硫酸葡聚糖介导的前激肽释放酶激活。由于HK与MoAb 115 - 21相互作用的解离常数(kd)比HK与前激肽释放酶的解离常数低10倍,我们的数据表明MoAb 115 - 21与HK的肽IV位点结合会增加血浆中游离前激肽释放酶的浓度,从而导致因子XIIa介导的前激肽释放酶激活效率降低。如此形成的激肽释放酶水平降低可能是抑制HK依赖的凝血活性以及硫酸葡聚糖接触激活后正常人血浆中HK裂解速率和程度降低的原因。因此,MoAb 115 - 21可能非常有用,尤其是因其对HK具有高亲和力,有助于进一步阐明HK和前激肽释放酶在接触激活以及与激肽相关的人类病理学中的作用。